EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 (A4166) is a highly potent and selective DOT1L histone methyltransferase inhibitor (IC50: 0.8 nM; Ki: 80 pM), engineered for targeted epigenetic intervention in leukemia models [APExBIO, product page]. Its selectivity (>37,000-fold vs. other methyltransferases) enables precise inhibition of H3K79 methylation, directly downregulating MLL-fusion target genes (Kim et al., 2018). In vivo, EPZ5676 induces complete tumor regression in MV4-11 xenograft models without marked toxicity. The compound’s solubility and stability parameters facilitate use in biochemical and cell-based assays. Its application advances the mechanistic study of epigenetic regulation in cancer and accelerates translational leukemia research [see contrast].

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is an essential lysine methyltransferase that catalyzes methylation of histone H3 at lysine 79 (H3K79). Aberrant H3K79 methylation is a hallmark of MLL (mixed lineage leukemia)-rearranged leukemias, where DOT1L activity maintains oncogenic gene expression programs (Kim et al., 2018). MLL fusion proteins recruit DOT1L to chromatin, leading to hypermethylation of H3K79 and transcriptional activation of leukemogenic genes. Targeted DOT1L inhibition interrupts this pathway, suppressing proliferation and survival of MLL-rearranged leukemia cells. Pharmacologic targeting of epigenetic enzymes such as DOT1L has transformed therapeutic strategies for aggressive leukemias [further details].

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 functions as a competitive inhibitor of the S-adenosyl methionine (SAM) binding pocket of DOT1L. By occupying this site, EPZ5676 induces conformational changes and exposes a unique hydrophobic pocket adjacent to the amino acid portion of SAM (APExBIO product doc). This mechanism ensures selectivity by preventing methyl group transfer to H3K79, thereby reducing methylation marks that drive leukemogenic gene expression. The compound does not significantly inhibit related methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, or WHSC1/1L1, as confirmed by >37,000-fold selectivity benchmarks [see comparison].

Evidence & Benchmarks

• EPZ5676 exhibits an in vitro IC50 of 0.8 nM and a Ki of 80 pM for DOT1L enzymatic activity inhibition (buffer: 50 mM Tris-HCl, pH 8.5, 25°C) (APExBIO).
• Demonstrates >37,000-fold selectivity versus structurally and functionally related methyltransferases (CARM1, EHMT1/2, etc.) (Kim et al., 2018).
• Inhibits H3K79 methylation and downregulates MLL-fusion target genes in acute leukemia cell lines (MV4-11 IC50: 3.5 nM, 4–7 day exposure) (histone-h2a.com).
• Induces complete tumor regression in nude rat MV4-11 xenograft models at 35–70 mg/kg/day intravenous dosing for 21 days; no significant toxicity or weight loss observed (APExBIO).
• Demonstrates robust cytotoxicity and antiproliferative effects in MLL-rearranged leukemia models, but not in cell lines lacking MLL translocations (sb-334867.com).

Applications, Limits & Misconceptions

EPZ5676 is validated for:

• Biochemical enzyme inhibition assays for DOT1L activity quantification.
• Cell proliferation and cytotoxicity studies in MLL-rearranged leukemia models.
• Translational research on H3K79 methylation and epigenetic gene regulation in cancer [expands troubleshooting].

Common Pitfalls or Misconceptions

• EPZ5676 is not effective against non-MLL-rearranged leukemia or solid tumors lacking DOT1L dependency.
• Water insolubility requires formulation in DMSO or ethanol; improper solvents may lead to precipitation or assay interference.
• Long-term stock solution storage above -20°C leads to potency loss.
• The compound does not inhibit histone demethylases (e.g., JIB-04 targets demethylases, not methyltransferases).
• Observed cytotoxicity is highly context-specific and not generalizable to all cancer cell lines.

This article extends prior discussions on EPZ5676’s mechanism and research utility by providing new comparative benchmarks and explicit guidance on limitations, unlike this overview and this mechanism-focused piece, which focus primarily on foundational studies and broad context.

Workflow Integration & Parameters

• Solubility: ≥28.15 mg/mL in DMSO; ≥50.3 mg/mL in ethanol (ultrasonic assistance recommended); insoluble in water.
• Form: Solid; molecular weight 562.71 Da.
• Storage: -20°C for powder; DMSO stock solutions stable below -20°C for several months.
• Recommended diluents: DMSO, ethanol (avoid aqueous buffers for primary dissolution).
• Assay usage: Biochemical DOT1L enzymatic assays, cell-based antiproliferative assays (MV4-11 cells, 3.5 nM, 4–7 days).

For detailed workflow troubleshooting, see the A4166 kit documentation and recent discussions on assay optimization (see troubleshooting section).

Conclusion & Outlook

EPZ5676 is a validated, high-specificity tool for dissecting DOT1L-mediated epigenetic regulation in MLL-rearranged leukemia. Its robust selectivity and reproducible biological effects make it a preferred reagent in both basic and translational research. Ongoing advances in epigenetic therapies underscore the need for such selective inhibitors. Researchers should apply EPZ5676 in relevant cellular contexts with attention to formulation and stability parameters. For further product details, ordering, and technical support, refer to the DOT1L inhibitor EPZ-5676 product page by APExBIO.